Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and PMBCL
NCT01965119Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Nov 2013
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in Hodgkin lymphoma (HL), primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Samsung Medical Center. Started Nov 2013; status: completed.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT01965119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01965119.